Answers are grounded in this paper and cite their sources.
Phase 2 study demonstrates safety and tolerability of luspatercept in adolescents with α-thalassemia, indicating potential for broader use in anemia treatment.
Introduction: α-thalassemia hemoglobin H (HbH) disease occurs when ≥2 of a patient's 4 α-globin alleles are abnormally expressed, leading to ineffective erythropoiesis and chronic anemia. There remains a significant unmet need for treatments to alleviate anemia in patients with α-thalassemia HbH disease. Luspatercept is approved for the treatment of anemia in adult patients with β-thalassemia who require red blood cell (RBC) transfusions in the USA, China (patients requiring ≤15 RBC units/24 wk), and in the EU for the treatment of anemia associated with transfusion-dependent (TD) and non-transfusion-dependent (NTD) β-thalassemia. Here we present data from 6 adolescent patients enrolled in an open-label, dose-confirmation cohort of a phase 2, multicenter study to determine the safety and tolerability of luspatercept for the treatment of patients with TD or NTD α-thalassemia HbH disease (NCT05664737). Methods: Eligible adolescent patients (age 12 to <18 y) had a diagnosis of α-thalassemia HbH disease. TD was defined as requiring ≥4 RBC events during the 24 wk prior to enrollment, having no transfusion-free period >56 d during the 24 wk prior to enrollment, and a history of regular transfusions for ≥2 y. NTD was defined as requiring <4 RBC events during the 24 wk prior to enrollment, being RBC transfusion-free during ≥8 wk prior to enrollment, and having mean baseline hemoglobin (Hb) ≤10 g/dL based on 2 measurements ≥1 wk apart within 4 wk prior to enrollment. Patients also had Karnofsky (≥16 y) or Lansky (<16 y) performance status score ≥50 at screening. Adolescent patients were enrolled in TD and NTD dose-confirmation cohorts (n=3 each) where they received a single 21-d cycle of treatment (1 dose of luspatercept at the recommended dose [RD] of 1.0 mg/kg subcutaneously [SC]) and were evaluated for safety and tolerability; the RD was determined from the dose-escalation and dose-confirmation results of luspatercept in adolescent patients with β-thalassemia (ACE-536-B-THAL-004). Following dose confirmation, enrollment began for the dose-expansion phase (n=30 in each TD and NDT cohort), where patients receive luspatercept at the RD SC every 21 d for 48 wk; after completing the dose-confirmation or dose-expansion phases, patients can subsequently enter a long-term treatment phase (≤5 y) and post-treatment follow-up period. Results: As of March 3, 2025, 3 adolescent patients were enrolled in each of the TD and NTD dose-confirmation cohorts. Median (range) age was 14 y (13–17) and 17 y (16–17), respectively. In the TD cohort all patients were male, and in the NTD cohort all were female. Median (range) baseline transfusion burden was 6.0 RBC units/24 wk (4.0–6.0) in the TD cohort; in the NTD cohort 1 patient received transfusions at baseline (2.0 units). All patients in the TD cohort had baseline Hb ≥8.5 g/dL; in the NTD cohort, 2 (66.7%) patients had baseline Hb <8.5 g/dL and 1 (33.3%) had baseline Hb ≥8.5 g/dL. Across both cohorts, only 1 (33.3%) patient (TD) had prior splenectomy. Median (range) serum ferritin at baseline was 785.5 μg/L (426.5–1535.5) for the TD cohort and 106.0 µg/L (23.5–584.0) for the NTD cohort; median (range) baseline liver iron concentration as measured by MRI was 8.2 mg/g dry weight (dw) (4.3–27.0) and 1.7 mg/g dw (1.6–3.5) for TD and NTD cohorts, respectively. All patients in the TD cohort and none in the NTD cohort received prior iron chelation therapy. All patients had ≥1 comorbidity at baseline. During the dose-confirmation period, within the 21 d from their first dose of study therapy, treatment-emergent adverse events (TEAEs) were reported in 2/6 patients (TD: one grade 1 dizziness; one grade 2 upper respiratory infection). No grade 3/4 TEAEs, dose-limiting toxicities (DLTs; defined as grade ≥3 hemolytic crises or other grade ≥3 AEs outside the expected safety profile occurring within 21 d of the first dose), serious TEAEs, or AEs of special interest (thromboembolic events, malignancies or pre-malignancies, extramedullary masses, and bone fractures) were reported in either cohort. Conclusions: In this analysis from the dose-confirmation phase of luspatercept in adolescent patients with TD and NTD α-thalassemia HbH disease, no DLTs or new safety signals were reported, suggesting that the RD of 1.0 mg/kg is well-tolerated in these patients. Enrollment in the TD and NTD dose-expansion cohorts is ongoing.
No takes yet. Share an insight, caveat, or question.
Lai et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: